PRINCIPIA BIOPHARMA

principia-biopharma-logo

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

#SimilarOrganizations #People #Financial #Website #More

PRINCIPIA BIOPHARMA

Social Links:

Industry:
Biopharma Biotechnology Life Science

Founded:
2008-01-01

Address:
South San Francisco, California, United States

Country:
United States

Website Url:
http://www.principiabio.com

Total Employee:
11+

Status:
Closed

Contact:
(650) 416-7700

Email Addresses:
info@principiabio.com

Total Funding:
127.8 M USD

Technology used in webpage:
SPF Apache Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Apache 2.4 Amazon SSL Gravity Forms Mimecast


Similar Organizations

algaeon-logo

Algaeon

Algaeon supplies high-value products derived from algae to companies in the human nutraceutical and fish feed industries.

artizan-biosciences-logo

Artizan Biosciences

Artizan Biosciences focuses on drug discovery and development for diseases involving the human intestinal microbiota.

demetrix-logo

Demetrix

Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.

echo-logo

Echo

Echo is a provider of an automated microscope intended for biological research and pathologies.

emmaus-medical-logo

Emmaus Medical

Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.

foxbio-logo

FoxBio

FoxBio is a Company that will develop Antoxerene’s collection of small molecules that target senescent cells.

olipass-logo

Olipass

OliPass Corporation is committed to revolutionize our views of life sciences and bring us great quality of life.


Current Advisors List

dan-becker_image

Dan Becker Board Member @ Principia Biopharma
Board_member
2017-01-01

martin-babler_image

Martin Babler Board Member @ Principia Biopharma
Board_member

simeon-george_image

Simeon George Board Member @ Principia Biopharma
Board_member
2011-01-01

shao-lee-lin_image

Shao-Lee Lin Board Member @ Principia Biopharma
Board_member
2019-04-01

peter-thompson_image

Peter Thompson Board Chairman @ Principia Biopharma
Board_member
2013-01-01

srinivas-akkaraju_image

Srinivas Akkaraju Board Member @ Principia Biopharma
Board_member

alan-colowick_image

Alan Colowick Board Chairman @ Principia Biopharma
Board_member
2017-02-01

Current Employees Featured

david-goldstein_image

David Goldstein
David Goldstein Sr.Vice President, Drug Discovery @ Principia Biopharma
Sr.Vice President, Drug Discovery
2011-03-01

olivia-ware_image

Olivia Ware
Olivia Ware Senior Vice President of BTK @ Principia Biopharma
Senior Vice President of BTK

not_available_image

Johannes Van Houte
Johannes Van Houte Vice President, Finance & Administration @ Principia Biopharma
Vice President, Finance & Administration

christopher-y-chai_image

Christopher Y. Chai
Christopher Y. Chai CFO @ Principia Biopharma
CFO

jack-taunton_image

Jack Taunton
Jack Taunton Founder and Board Observer @ Principia Biopharma
Founder and Board Observer

betsy-santos_image

Betsy Santos
Betsy Santos Senior Vice President of People @ Principia Biopharma
Senior Vice President of People

martin-babler_image

Martin Babler
Martin Babler CEO @ Principia Biopharma
CEO
2011-04-01

david-goldstein_image

David Goldstein
David Goldstein Chief Scientific Officer @ Principia Biopharma
Chief Scientific Officer
2016-03-01

Founder


not_available_image

Bernard Cambou

jack-taunton_image

Jack Taunton

Stock Details


Company's stock symbol is NASDAQ:PRNB

Investors List

bioinnovation-capital_image

Mission BioCapital

Mission BioCapital investment in Venture Round - Principia Biopharma

sr-one_image

SR One

SR One investment in Series B - Principia Biopharma

sofinnova-ventures_image

Sofinnova Investments

Sofinnova Investments investment in Series B - Principia Biopharma

baker-brothers-investments_image

Baker Brothers Advisors LLC

Baker Brothers Advisors LLC investment in Series B - Principia Biopharma

morgenthaler-ventures_image

Morgenthaler Ventures

Morgenthaler Ventures investment in Series B - Principia Biopharma

new-leaf-venture-partners_image

New Leaf Venture Partners

New Leaf Venture Partners investment in Series B - Principia Biopharma

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series B - Principia Biopharma

sr-one_image

SR One

SR One investment in Series B - Principia Biopharma

morgenthaler-ventures_image

Morgenthaler Ventures

Morgenthaler Ventures investment in Series B - Principia Biopharma

sofinnova-ventures_image

Sofinnova Investments

Sofinnova Investments investment in Series B - Principia Biopharma

Official Site Inspections

http://www.principiabio.com

  • Host name: ec2-54-247-151-159.eu-west-1.compute.amazonaws.com
  • IP address: 54.247.151.159
  • Location: Dublin Ireland
  • Latitude: 53.3338
  • Longitude: -6.2488
  • Timezone: Europe/Dublin
  • Postal: D02

Loading ...

More informations about "Principia Biopharma"

Sanofi to Acquire Principia for Autoimmune R&D | Sanofi

Aug 17, 2005 Sanofi Media Relations Contact Ashleigh Koss Tel.: +1 908 205 2572 Ashleigh.Koss@sanofi.com Nicolas Kressmann Tel: +1 732 532 5318 …See details»

Principia Biopharma - Crunchbase Company Profile

Oct 30, 2012 Organization. Principia Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Principia Biopharma is dedicated to bringing oral therapies to patients …See details»

Sanofi completes Principia Biopharma Inc. acquisition

Sep 28, 2013 Sanofi completes Principia Biopharma Inc. acquisition *Principia Biopharma Inc. is now a wholly owned subsidiary of Sanofi. PARIS – September 28, 2020 – Sanofi announced …See details»

Principia Biopharma - LinkedIn

Principia Biopharma Biotechnology South San Francisco, California 4,741 followers Bringing transformative oral therapies to patients with significant unmet medical needs in immune-mediated diseases.See details»

Principia Biopharma - Overview, News & Similar companies

Nov 23, 2020 www.principiabio.com. Revenue <$5 Million. Stock Symbol PRNB. Industry Pharmaceuticals Healthcare . Recent News & Media. Patient Enrollment Concluded Early in …See details»

Principia Biopharma Company Overview, Contact …

Oct 16, 2019 John.Doe@principiabio.com: 48%. FLast@principiabio.com: JDoe@principiabio.com: 2%. See more formats. Frequently Asked Questions Where is Principia Biopharma 's headquarters located? Principia Biopharma 's …See details»

Principia Biopharma - PitchBook

Information on acquisition, funding, cap tables, investors, and executives for Principia Biopharma. Use the PitchBook Platform to explore the full profile.See details»

Sanofi to commence tender offer for acquisition of Principia …

Aug 28, 2005 Sanofi has announced that SAR442168 has entered Phase 3 clinical trials in multiple sclerosis. PRN473 Topical, a topical reversible covalent BTK inhibitor designed for …See details»

Principia BioPharma - Craft

Principia BioPharma $35.16 m in annual revenue in FY 2019. See insights on Principia BioPharma including office locations, competitors, revenue, financials, executives, subsidiaries …See details»

Principia Biopharma Inc: Overview - GlobalData

Website www.principiabio.com Telephone 1 650 4167700. Industry Pharmaceuticals and Healthcare. Revenue (2019) $5.2M. Gain access to our premium ...See details»

Sanofi goes all in on Principia, paying $3.7B to take full …

Aug 17, 2020 Sanofi has struck a deal to buy its partner Principia Biopharma for $3.7 billion in cash. The takeover will give Sanofi full ownership of a BTK inhibitor it moved into a raft of phase 3 multiple ...See details»

Sanofi, seeking control of key drug, to buy Principia for $3.7B

Aug 17, 2020 Dive Brief: Sanofi on Monday said it will pay $3.68 billion to acquire partner Principia Biopharma in a deal that gives the French drugmaker full control over a promising …See details»

Sanofi to acquire Principia Biopharma - Nasdaq

Aug 17, 2020 Sanofi to acquire Principia Biopharma. Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor …See details»

Principia Biopharma | Insights

Nov 7, 2024 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»

IR call on the acquisition of Principia Biopharma Inc. - Sanofi

Jan 22, 2018 Forward looking statements This presentation contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may …See details»

Principia Announces First Patient Dosed in Phase 2A Trial

Sep 17, 2020 For more information, please visit www.principiabio.com. Forward-Looking Statements. This press release contains forward-looking statements. Forward-looking …See details»

Principia Announces Positive Data from its Phase 2 Part B

Jun 12, 2020 Clear dose-response combined with decreased daily corticosteroid usage. Response rate increased with extended duration of treatment to six months while maintaining …See details»

Sanofi to acquire Principia Biopharma - GlobeNewswire

Aug 17, 2020 Sanofi Media Relations Contact Ashleigh Koss Tel.: +1 908 205 2572 Ashleigh.Koss@sanofi.com Nicolas Kressmann Tel: +1 732 532 5318 …See details»

Principia Biopharma, Inc. (Principia Biopharma, Inc.) - 药物管线_专 …

This was a Ph2a study that consists of a double-blind, intra-patient placebo-controlled treatment period and an open-label uncontrolled treatment period with objective to evaluate the safety, …See details»

A Leading Immunology Healthcare Company | Sanofi

Nov 13, 2024 Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a …See details»

linkstock.net © 2022. All rights reserved